579
Views
4
CrossRef citations to date
0
Altmetric
ORIGINAL ARTICLE

Economic assessment of doripenem versus imipenem in the treatment of ventilator-associated pneumonia

, , , , , , , & show all
Pages 142-147 | Published online: 08 Feb 2010

References

  • Safdar N, Dezfulian C, Collard HR, Saint S. Clinical and economic consequences of ventilator-associated pneumonia: a systematic review. Crit Care Med 2005;33:2184-2193
  • Rello J, Ollendorf DA, Oster G, Epidemiology and outcomes of ventilator-associated pneumonia in a large US database. Chest 2002;122:1883-1885
  • MacIntyre NR. Ventilator-associated pneumonia: the role of ventilator management strategies. Respir Care 2005;50:766-773
  • Shorr AF, Susla GM, Kollef MH. Linezolid for treatment of ventilator-associated pneumonia: a cost-effective alternative to vancomycin. Crit Care Med 2004;32:137-143
  • Kollef MH. What is ventilator-associated pneumonia and why is it important? Respir Care 2005;50:714-724
  • Carlet J, Ben Ali A, Chalfine A. Epidemiology and control of antibiotic resistance in the intensive care unit. Curr Opin Infect Dis 2004;17:309-316
  • Kollef MH, Fraser VJ. Antibiotic resistance in the intensive care unit. Ann Intern Med 2001;134:298-314
  • Park D. Antimicrobial treatment of ventilator-associated pneumonia. Respir Care 2005;50:933-953
  • American Thoracic Society; Infectious Diseases Society of America. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 2005;171:388-416
  • Johnson & Johnson Pharmaceutical Research & Development, LLC (2008) Doripenem in the Treatment of Ventilator-Associated Pneumonia. ClinicalTrials.gov Identifier NCT00211016. Available at: http://clinicaltrials.gov/ct2/show/NCT00211016
  • Chastre J, Wunderink R, Prokocimer P, Efficacy and safety of intravenous infusion of doripenem versus imipenem in ventilator-associated pneumonia: a multicenter, randomized study. Crit Care Med 2008;36:1089-1096
  • Sakyo S, Tomita H, Tanimoto K, Potency of carbapenems for the prevention of carbapenem-resistant mutants of Pseudomonas aeruginosa: the high potency of a new carbapenem doripenem. Jpn J Antibiotics 2006;59:220-228
  • Merchant S, Gast C, Nathwani D, Hospital resource utilization with doripenem versus imipenem in the treatment of ventilator-associated pneumonia. Clin Ther 2008;30:717-733
  • Hjelmgren J, Berggren F, Andersson F. Health economic guidelines—similarities, differences and some implications. Value Health 2001;4:225-250
  • Talmor D, Shapiro N, Greenberg D, When is critical care medicine cost-effective? A systematic review of the cost-effectiveness literature. Crit Care Med 2006;34:2738-2747
  • First DataBank. National Drug Data File (NDDF). Available at: http://www.firstdatabank.com/products/nddf/. Accessed February 11, 2008
  • Paladino JA, Adelman MH, Schentag JJ, Iannini PB. Direct costs in patients hospitalised with community-acquired pneumonia after non-response to outpatient treatment with macrolide antibacterials in the US. Pharmacoeconomics 2007;25:677-683
  • Dasta JF, McLaughlin TP, Mody SH, Piech CT. Daily cost of an intensive care unit day: the contribution of mechanical ventilation. Crit Care Med 2005;33:1266-1271
  • Doubilet P, Begg CB, Weinstein MC,B, Probabilistic sensitivity analysis using Monte Carlo simulation: a practical approach. Med Decis Making 1985;5:157-177
  • Edwards SJ, Campbell HE, Plumb JM. Cost-utility analysis comparing meropenem with imipenem plus cilastatin in the treatment of severe infections in intensive care. Eur J Health Econ 2006;7:72-78
  • Graham E, Whalen E, Smith ME. Comparison of costs between ciprofloxacin and imipenem for the treatment of severe pneumonia in hospitalized patients. Pharmacotherapy 1994;14: 370-371
  • Caldwell JW, Singh S, Johnson RH. Clinical and economic evaluation of subsequent infection following intravenous ciprofloxacin or imipenem therapy in hospitalized patients with severe pneumonia. J Antimicrob Chemother 1999;43(Suppl A): 129-134
  • Norrby SR, Eriksson M, Ottosson E. Imipenem/cilastatin versus gentamicin/clindamycin: a cost effectiveness study. Scand J Infect Dis 1986;18:371-374
  • Rodloff AC, Laubenthal HJ, Bastian A, [Comparative study of the cost-/effectiveness relationship of initial therapy with imipenem/cilastatin in nosocomial pneumonia. Group study.] Anasthesiol Intensivmed Notfallmed Schmerzther 1996;31:172-180

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.